Analyst Price Targets — BIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 16, 2026 12:43 pm | Brandon Couillard | Wells Fargo | $320.00 | $256.56 | TheFly | Bio-Rad price target lowered to $320 from $340 at Wells Fargo |
| February 13, 2026 2:33 pm | — | UBS | $335.00 | $259.64 | TheFly | Bio-Rad price target lowered to $335 from $350 at UBS |
| October 30, 2025 10:28 am | — | Wells Fargo | $340.00 | $319.47 | TheFly | Bio-Rad price target raised to $340 from $265 at Wells Fargo |
| October 1, 2024 5:34 am | Patrick Donnelly | Citigroup | $400.00 | $338.58 | StreetInsider | Citi Upgrades Bio-Rad Labs (BIO) to Buy |
| December 7, 2022 4:42 am | — | RBC Capital | $565.00 | $399.59 | Benzinga | RBC Capital Initiates Coverage On Bio-Rad Laboratories with Outperform Rating, Announces Price Target of $565 |
Latest News for BIO
HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present at the BIO…
Examine Bio-Rad's (BIO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.
Bio-Rad Laboratories, Inc. (NYSE: BIO - Get Free Report) has earned a consensus recommendation of "Hold" from the six research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.